60 Degrees Pharmaceuticals (SXTP) Amortizatization of Intangibles (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Amortizatization of Intangibles of $9165.0 for Q1 2026, down 9.28% year-over-year from $10103.0 in Q1 2025, and up 9.13% quarter-over-quarter from $8398.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Amortizatization of Intangibles for 5 consecutive years, with $9165.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 9.28% year-over-year to $9165.0; the TTM figure through Mar 2026 stood at $38610.0 (down 4.43% YoY), while the FY2025 annual figure was $39548.0, up 2.72% from the prior year.
- Amortizatization of Intangibles grew to $9165.0 in Q1 2026 per SXTP's latest filing, from $8398.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $494758.0 in Q3 2022 and bottomed at -$816036.0 in Q4 2022.
- Historically, Amortizatization of Intangibles has averaged -$13660.4 across 5 years, with a median of $9472.0 in 2024.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles slumped 98.5% — and 2024, when it soared 1138.17%.
- 60 Degrees Pharmaceuticals' Amortizatization of Intangibles stood at -$816036.0 in 2022, then surged by 101.05% to $8551.0 in 2023, then advanced by 22.77% to $10498.0 in 2024, then dropped by 20.0% to $8398.0 in 2025, then rose by 9.13% to $9165.0 in 2026.
- Business Quant data shows SXTP's Amortizatization of Intangibles at $9165.0 in Q1 2026, $8398.0 in Q4 2025, and $10605.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 13,860.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,165.00 |
| Mar 31, 2026 | 9,165.00 |
| Dec 31, 2025 | 8,398.00 |
| Dec 31, 2025 | 8,398.00 |
| Sep 30, 2025 | 10,605.00 |
| Sep 30, 2025 | 10,605.00 |
| Jun 30, 2025 | 10,442.00 |
| Jun 30, 2025 | 10,442.00 |
| Mar 31, 2025 | 10,103.00 |
| Mar 31, 2025 | 10,103.00 |
| Dec 31, 2024 | 10,498.00 |
| Dec 31, 2024 | 10,498.00 |
| Sep 30, 2024 | 10,325.00 |
| Sep 30, 2024 | 10,325.00 |
| Jun 30, 2024 | 9,472.00 |
| Jun 30, 2024 | 9,472.00 |
| Mar 31, 2024 | 8,207.00 |
| Mar 31, 2024 | 8,207.00 |
| Dec 31, 2023 | 8,551.00 |
| Dec 31, 2023 | 8,551.00 |